Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1997 Apr;105(Suppl 3):601–605. doi: 10.1289/ehp.97105s3601

A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer.

G Ursin 1, S London 1, F Z Stanczyk 1, E Gentzschein 1, A Paganini-Hill 1, R K Ross 1, M C Pike 1
PMCID: PMC1469909  PMID: 9168002

Abstract

The two main pathways for metabolizing estrogen are via 16alpha-hydroxylation and 2-hydroxylation. The 16alpha-hydroxy metabolites are biologically active; the 2-hydroxy metabolites are not. It is suggested that women who metabolize a larger proportion of their endogenous estrogen via the 16alpha-hydroxy pathway may be at significantly elevated risk of breast cancer compared with women who metabolize proportionally more estrogen via the 2-hydroxy pathway. In particular, it is suggested that the ratio of urinary 2-hydroxyestrone (2-OHE1) to 16alpha-hydroxyestrone (16alpha-OHE1) is an index of reduced breast cancer risk. This pilot study compared this ratio in postmenopausal women diagnosed with breast cancer to those of healthy controls. Urinary concentrations of estrone (E1), 17beta-estradiol (E2) and estriol (E3) were also quantified. White women who were subjects in a previous breast cancer case-control study at our institution were eligible for inclusion. All participants provided a sample of their first morning urine. The results from the first 25 cases and 23 controls are presented here. The ratio of 2-OHE1 to 16alpha-OHE1 was 12% lower in the cases (p=0.58). However, urinary E1 was 30% higher (p=0.10), E2 was 58% higher (p=0.07), E3 was 15% higher (p=0.48), and the sum of E1, E2, and E3 was 22% higher (p=0.16) in the cases. These preliminary results do not support the hypothesis that the ratio of the two hydroxylation metabolites (2-OHE1/16alpha-OHE1) is an important risk factor for breast cancer or that it is a better predictor of breast cancer risk than levels of E1, E2 and E3 measured in urine.

Full text

PDF
601

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami H. O., Johansson E. D., Vegelius J., Victor A. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. Ups J Med Sci. 1979;84(3):259–274. doi: 10.3109/03009737909179163. [DOI] [PubMed] [Google Scholar]
  2. Adlercreutz H., Fotsis T., Höckerstedt K., Hämäläinen E., Bannwart C., Bloigu S., Valtonen A., Ollus A. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem. 1989;34(1-6):527–530. doi: 10.1016/0022-4731(89)90138-6. [DOI] [PubMed] [Google Scholar]
  3. Argüelles A. E., Poggi U. L., Saborida C., Hoffman C., Chekherdemian M., Blanchard O. Endocrine profiles and breast cancer. Lancet. 1973 Jan 27;1(7796):165–168. doi: 10.1016/s0140-6736(73)90002-0. [DOI] [PubMed] [Google Scholar]
  4. Bernstein L., Ross R. K., Pike M. C., Brown J. B., Henderson B. E. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br J Cancer. 1990 Feb;61(2):298–302. doi: 10.1038/bjc.1990.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bradlow H. L., Hershcopf R. E., Fishman J. F. Oestradiol 16 alpha-hydroxylase: a risk marker for breast cancer. Cancer Surv. 1986;5(3):573–583. [PubMed] [Google Scholar]
  6. Bradlow H. L., Hershcopf R. J., Martucci C. P., Fishman J. Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6295–6299. doi: 10.1073/pnas.82.18.6295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bradlow H. L., Hershcopf R., Martucci C., Fishman J. 16 alpha-hydroxylation of estradiol: a possible risk marker for breast cancer. Ann N Y Acad Sci. 1986;464:138–151. doi: 10.1111/j.1749-6632.1986.tb16001.x. [DOI] [PubMed] [Google Scholar]
  8. Bruning P. F., Bonfrèr J. M., Hart A. A. Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk. Br J Cancer. 1985 Apr;51(4):479–484. doi: 10.1038/bjc.1985.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cassidenti D. L., Vijod A. G., Vijod M. A., Stanczyk F. Z., Lobo R. A. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 1):1953–1960. doi: 10.1016/0002-9378(90)90780-b. [DOI] [PubMed] [Google Scholar]
  10. Clark J. H., Paszko Z., Peck E. J., Jr Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol. Endocrinology. 1977 Jan;100(1):91–96. doi: 10.1210/endo-100-1-91. [DOI] [PubMed] [Google Scholar]
  11. Drafta D., Schindler A. E., Milcu S. M., Keller E., Stroe E., Horodniceanu E., Bălănescu I. Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem. 1980 Jul;13(7):793–802. doi: 10.1016/0022-4731(80)90231-9. [DOI] [PubMed] [Google Scholar]
  12. England P. C., Skinner L. G., Cottrell K. M., Sellwood R. A. Serum oestradiol-17 beta in women with benign and malignant breast disease. Br J Cancer. 1974 Dec;30(6):571–576. doi: 10.1038/bjc.1974.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. FISHMAN J., HELLMAN L., ZUMOFF B., GALLAGHER T. F. Influence of thyroid hormone on estrogen metabolism in man. J Clin Endocrinol Metab. 1962 Apr;22:389–392. doi: 10.1210/jcem-22-4-389. [DOI] [PubMed] [Google Scholar]
  14. Fishman J., Martucci C. Biological properties of 16 alpha-hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab. 1980 Sep;51(3):611–615. doi: 10.1210/jcem-51-3-611. [DOI] [PubMed] [Google Scholar]
  15. Galbraith R. A., Michnovicz J. J. The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med. 1989 Aug 3;321(5):269–274. doi: 10.1056/NEJM198908033210501. [DOI] [PubMed] [Google Scholar]
  16. Grattarola R., Secreto G., Recchione C., Castellini W. Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet Gynecol. 1974 Jan 15;118(2):173–178. [PubMed] [Google Scholar]
  17. Grönroos M., Aho A. J. Estrogen metabolism in postmenopausal women with primary and recurrent breast cancer. Eur J Cancer. 1968 Oct;4(5):523–527. doi: 10.1016/0014-2964(68)90008-x. [DOI] [PubMed] [Google Scholar]
  18. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988 Jan 15;48(2):246–253. [PubMed] [Google Scholar]
  19. Hoffman A. R., Majchrowicz E., Poth M. A., Paul S. M. Ethanol reduces hepatic estrogen-2-hydroxylase activity in the male rat. Life Sci. 1981 Aug 24;29(8):789–794. doi: 10.1016/0024-3205(81)90034-5. [DOI] [PubMed] [Google Scholar]
  20. Katagiri H., Stanczyk F. Z., Goebelsmann U. Estriol in pregnancy. III. Development, comparison and use of specific antisera for rapid radioimmunoassay of unconjugated estriol in pregnancy plasma. Steroids. 1974 Aug;24(2):225–238. doi: 10.1016/0039-128x(74)90105-6. [DOI] [PubMed] [Google Scholar]
  21. Klug T. L., Bradlow H. L., Sepkovic D. W. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16 alpha-hydroxyestrone in urine. Steroids. 1994 Nov;59(11):648–655. doi: 10.1016/0039-128x(94)90021-3. [DOI] [PubMed] [Google Scholar]
  22. Longcope C., Gorbach S., Goldin B., Woods M., Dwyer J., Morrill A., Warram J. The effect of a low fat diet on estrogen metabolism. J Clin Endocrinol Metab. 1987 Jun;64(6):1246–1250. doi: 10.1210/jcem-64-6-1246. [DOI] [PubMed] [Google Scholar]
  23. Longnecker M. P., Paganini-Hill A., Ross R. K. Lifetime alcohol consumption and breast cancer risk among postmenopausal women in Los Angeles. Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):721–725. [PubMed] [Google Scholar]
  24. Lubin F., Ruder A. M., Wax Y., Modan B. Overweight and changes in weight throughout adult life in breast cancer etiology. A case-control study. Am J Epidemiol. 1985 Oct;122(4):579–588. doi: 10.1093/oxfordjournals.aje.a114137. [DOI] [PubMed] [Google Scholar]
  25. MARMORSTON J., CROWLEY L. G., MYERS S. M., STERN E., HOPKINS C. E. II. URINARY EXCRETION OF ESTRONE, ESTRADIOL, AND ESTRIOL BY PATIENTS WITH BREAST CANCER AND BENIGN BREAST DISEASE. Am J Obstet Gynecol. 1965 Jun 15;92:460–467. doi: 10.1016/s0002-9378(16)34835-9. [DOI] [PubMed] [Google Scholar]
  26. Malarkey W. B., Schroeder L. L., Stevens V. C., James A. G., Lanese R. R. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res. 1977 Dec;37(12):4655–4659. [PubMed] [Google Scholar]
  27. Martucci C., Fishman J. Direction of estradiol metabolism as a control of its hormonal action--uterotrophic activity of estradiol metabolites. Endocrinology. 1977 Dec;101(6):1709–1715. doi: 10.1210/endo-101-6-1709. [DOI] [PubMed] [Google Scholar]
  28. McFadyen I. J., Forrest A. P., Prescott R. J., Golder M. P., Groom G. V., Fahmy D. R., Griffiths K. Circulating hormone concentrations in women with breast cancer. Lancet. 1976 May 22;1(7969):1100–1102. doi: 10.1016/s0140-6736(76)90064-7. [DOI] [PubMed] [Google Scholar]
  29. Michnovicz J. J., Bradlow H. L. Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer. 1991;16(1):59–66. doi: 10.1080/01635589109514141. [DOI] [PubMed] [Google Scholar]
  30. Moore J. W., Clark G. M., Bulbrook R. D., Hayward J. L., Murai J. T., Hammond G. L., Siiteri P. K. Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int J Cancer. 1982 Jan 15;29(1):17–21. doi: 10.1002/ijc.2910290105. [DOI] [PubMed] [Google Scholar]
  31. Morreal C. E., Dao T. L., Nemoto T., Lonergan P. A. Urinary excretion of estrone, estradiol, and estriol in postmenopausal women with primary breast cancer. J Natl Cancer Inst. 1979 Nov;63(5):1171–1174. [PubMed] [Google Scholar]
  32. Musey P. I., Collins D. C., Bradlow H. L., Gould K. G., Preedy J. R. Effect of diet on oxidation of 17 beta-estradiol in vivo. J Clin Endocrinol Metab. 1987 Oct;65(4):792–795. doi: 10.1210/jcem-65-4-792. [DOI] [PubMed] [Google Scholar]
  33. Niwa T., Bradlow H. L., Fishman J., Swaneck G. E. Induction and inhibition of estradiol hydroxylase activities in MCF-7 human breast cancer cells in culture. Steroids. 1990 Jul;55(7):297–302. doi: 10.1016/0039-128x(90)90032-7. [DOI] [PubMed] [Google Scholar]
  34. Osborne M. P., Bradlow H. L., Wong G. Y., Telang N. T. Upregulation of estradiol C16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst. 1993 Dec 1;85(23):1917–1920. doi: 10.1093/jnci/85.23.1917. [DOI] [PubMed] [Google Scholar]
  35. Osborne M. P., Telang N. T., Kaur S., Bradlow H. L. Influence of chemopreventive agents on estradiol metabolism and mammary preneoplasia in the C3H mouse. Steroids. 1990 Mar;55(3):114–119. doi: 10.1016/0039-128x(90)90006-w. [DOI] [PubMed] [Google Scholar]
  36. PERSSON B. H., RISHOLM L. OOPHORECTOMY AND CORTISONE TREATMENT AS A METHOD OF ELIMINATING OESTROGEN PRODUCTION IN PATIENTS WITH BREAST CANCER. Acta Endocrinol (Copenh) 1964 Sep;47:15–26. doi: 10.1530/acta.0.0470015. [DOI] [PubMed] [Google Scholar]
  37. Reed M. J., Beranek P. A., Cheng R. W., Ghilchik M. W., James V. H. The distribution of oestradiol in plasma from postmenopausal women with or without breast cancer: relationships with metabolic clearance rates of oestradiol. Int J Cancer. 1985 Apr 15;35(4):457–460. doi: 10.1002/ijc.2910350407. [DOI] [PubMed] [Google Scholar]
  38. Reed M. J., Cheng R. W., Noel C. T., Dudley H. A., James V. H. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res. 1983 Aug;43(8):3940–3943. [PubMed] [Google Scholar]
  39. Schneider J., Kinne D., Fracchia A., Pierce V., Anderson K. E., Bradlow H. L., Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A. 1982 May;79(9):3047–3051. doi: 10.1073/pnas.79.9.3047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Secreto G., Recchione C., Cavalleri A., Miraglia M., Dati V. Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer. 1983 Feb;47(2):269–275. doi: 10.1038/bjc.1983.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Siiteri P. K., Simberg N., Murai J. Estrogens and breast cancer. Ann N Y Acad Sci. 1986;464:100–105. doi: 10.1111/j.1749-6632.1986.tb15997.x. [DOI] [PubMed] [Google Scholar]
  42. Stanczyk F. Z., Shoupe D., Nunez V., Macias-Gonzales P., Vijod M. A., Lobo R. A. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol. 1988 Dec;159(6):1540–1546. doi: 10.1016/0002-9378(88)90591-1. [DOI] [PubMed] [Google Scholar]
  43. Thijssen J. H., Poortman J., Schwarz F. Androgens in postmenopausal breast cancer: excretion, production and interaction with estrogens. J Steroid Biochem. 1975 May;6(5):729–734. doi: 10.1016/0022-4731(75)90060-6. [DOI] [PubMed] [Google Scholar]
  44. Trichopoulos D., MacMahon B., Cole P. Menopause and breast cancer risk. J Natl Cancer Inst. 1972 Mar;48(3):605–613. [PubMed] [Google Scholar]
  45. Wysowski D. K., Comstock G. W., Helsing K. J., Lau H. L. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol. 1987 May;125(5):791–799. doi: 10.1093/oxfordjournals.aje.a114596. [DOI] [PubMed] [Google Scholar]
  46. Ziegler R. G., Rossi S. C., Fears T. R., Bradlow H. L., Adlercreutz H., Sepkovic D., Kiuru P., Wahala K., Vaught J. B., Donaldson J. L. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Environ Health Perspect. 1997 Apr;105 (Suppl 3):607–614. doi: 10.1289/ehp.97105s3607. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES